Sanofi (NASDAQ:SNY) Given Average Recommendation of “Moderate Buy” by Brokerages

Sanofi (NASDAQ:SNY) has received an average rating of “Moderate Buy” from the four analysts that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $57.50.

Several brokerages have commented on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th.

Sanofi Price Performance

SNY stock opened at $48.72 on Thursday. The business’s fifty day moving average price is $53.17 and its 200 day moving average price is $52.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $123.64 billion, a PE ratio of 24.86, a P/E/G ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.55 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 4.29 EPS for the current year.

Institutional Investors Weigh In On Sanofi

A number of large investors have recently modified their holdings of the company. Manning & Napier Advisors LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth about $13,725,000. GFS Advisors LLC increased its stake in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after purchasing an additional 11,655 shares during the last quarter. Atria Investments Inc raised its holdings in Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after purchasing an additional 23,463 shares in the last quarter. Legacy Capital Wealth Partners LLC lifted its position in shares of Sanofi by 114.2% during the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after buying an additional 12,942 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Sanofi by 15.2% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock valued at $5,673,000 after buying an additional 15,439 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.